MCK — McKesson Corporation

McKesson Q2 Fiscal 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Consolidated Revenues: Increased 10% year-over-year to $103 billion.
• Adjusted Earnings Per Diluted Share: Rose 39% to $9.86.
• Operating Profit: Reached a record $1.6 billion, up 26% year-over-year.
• Gross Profit: Increased 9% to $3.5 billion.
• Free Cash Flow: $2.2 billion, with $196 million in capital expenditures.
• Cash Position: Ended the quarter with $4 billion in cash and cash equivalents.
• Segment Performance:
  • North American Pharmaceutical: Revenues of $86.5 billion (+8%); operating profit of $851 million (+13%).
  • Oncology and Multispecialty: Revenues of $12 billion (+32%); operating profit of $397 million (+71%).
  • Prescription Technology Solutions: Revenues of $1.4 billion (+9%); operating profit of $261 million (+20%).
  • Medical-Surgical Solutions: Revenues flat at $2.9 billion; operating profit increased 2% to $249 million.

2. Strategic Updates and Business Highlights

• New Reporting Structure: Introduced to enhance transparency and focus on growth areas, specifically oncology and multispecialty, and biopharma services.
• Oncology and Multispecialty Segment: Focus on expanding distribution capabilities and enhancing patient care through initiatives like InspiroCare and a new cold chain facility for cell and gene therapies.
• Biopharma Services: Continued investment in technology and automation to streamline access to therapies and improve patient support services.
• Medical-Surgical Solutions Separation: Progressing towards an IPO to separate this business, expected to complete by the second half of calendar 2027.

3. Forward Guidance and Outlook

• Adjusted Earnings Per Diluted Share Guidance: Increased to $38.35 to $38.85 for fiscal 2026, reflecting a 16% to 18% growth year-over-year.
• Revenue Growth Expectation: Projected at 11% to 15% for fiscal 2026.
• Operating Profit Growth: Anticipated at 12% to 16%.
• Segment Guidance:
  • North American Pharmaceutical: Revenue growth of 10% to 14%.
  • Oncology and Multispecialty: Revenue growth of 27% to 31%.
  • Prescription Technology Solutions: Revenue growth of 9% to 13%.
  • Medical-Surgical Solutions: Revenue growth at the low end of 2% to 6%.

4. Bad News, Challenges, or Points of Concern

• Medical-Surgical Solutions: Experiencing softer demand for illness season products, including vaccines and testing, which could impact revenue and profit growth.
• Market Decisions: Exited two markets within the U.S. oncology network, which may affect future growth potential.
• Investment Needs: Anticipated higher investment levels in the second half of the year could impact margins, despite strong first-half performance.
• Regulatory Changes: Compliance with the Drug Supply Chain Security Act represents a significant investment and operational challenge.

5. Notable Q&A Insights

• Margin Expansion: Operating margin growth in core segments attributed to a favorable mix of technology services and increased demand for access programs, particularly for GLP-1 medications.
• Oncology Segment Performance: Strong growth driven by acquisitions and organic growth, with expectations aligned with long-term guidance.
• Health System Strength: Notable performance in the health system segment, contributing positively to overall results.
• Tax Rate Guidance: Anticipated to be higher in the third quarter due to timing of discrete tax items, with a full-year effective tax rate now projected at 18% to 19%.
• Cash Pay Channel Impact: Management does not foresee significant impacts on prior authorization business from potential increases in cash pay patients.

This summary encapsulates McKesson's strong performance in Q2 2026, strategic initiatives, and outlook while addressing challenges and insights from the Q&A session.